Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 12,144,813 with an expected expiration date of no earlier than 2043. The claims of the patent cover the method of using onvansertib in combination with bevacizumab (bev) for the treatment of KRAS mutated metastatic colorectal cancer (mCRC) patients who have not previously been treated with bev. “We are pleased to announce the strengthening of our intellectual property portfolio for onvansertib, an important milestone in our mission to advance this innovative therapy to the first-line setting in combination with standard of care for RAS-mutated mCRC patients,” said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology. “This newly issued patent underscores
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]Yahoo! Finance
- CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/7/24 - Beat
CRDF
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form SCHEDULE
- 12/16/24 - Form 4
- CRDF's page on the SEC website